US20110245580A1 - Medical device for delivering drug and/or performing physical therapy - Google Patents
Medical device for delivering drug and/or performing physical therapy Download PDFInfo
- Publication number
- US20110245580A1 US20110245580A1 US13/164,293 US201113164293A US2011245580A1 US 20110245580 A1 US20110245580 A1 US 20110245580A1 US 201113164293 A US201113164293 A US 201113164293A US 2011245580 A1 US2011245580 A1 US 2011245580A1
- Authority
- US
- United States
- Prior art keywords
- patient
- medical device
- parameter
- drug
- stimulus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 229940079593 drug Drugs 0.000 title claims abstract description 53
- 238000000554 physical therapy Methods 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 11
- 239000003349 gelling agent Substances 0.000 claims description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 229960001631 carbomer Drugs 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 5
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 230000006870 function Effects 0.000 abstract description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 102000004877 Insulin Human genes 0.000 abstract description 3
- 108090001061 Insulin Proteins 0.000 abstract description 3
- 229940125396 insulin Drugs 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 description 19
- 239000007788 liquid Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 9
- 238000004891 communication Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 150000004804 polysaccharides Chemical class 0.000 description 4
- 238000005086 pumping Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010407 ammonium alginate Nutrition 0.000 description 2
- 239000000728 ammonium alginate Substances 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003990 capacitor Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000010408 potassium alginate Nutrition 0.000 description 2
- 239000000737 potassium alginate Substances 0.000 description 2
- 230000036316 preload Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 235000017367 Guainella Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 1
- 229940043234 carbomer-940 Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003989 dielectric material Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000001145 finger joint Anatomy 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14539—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
- A61B5/4261—Evaluating exocrine secretion production
- A61B5/4266—Evaluating exocrine secretion production sweat secretion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4869—Determining body composition
- A61B5/4875—Hydration status, fluid retention of the body
- A61B5/4878—Evaluating oedema
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/01—Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue
Definitions
- This invention relates to medical device for use with a patient for delivering drug and/or performing physical therapy.
- this invention provides a medical device for use with a patient for performing at least one of the functions of delivering drug and performing physical therapy to the patient including:
- At least one sensor for measuring at least one parameter from the patient
- an analyzer for analyzing the parameter to determine appropriate function to be carried out on the patient by said medical device
- At least one actuator to perform at least one of the functions of delivering drug and performing physical therapy.
- the medical device of this invention may further include a drug storage unit for storing at least one drug, said drug storage unit being operatively connected to the actuator for delivering said drug to the patient.
- the parameter is selected from the group consisting of electrical current or resistance, temperature, pressure, tension, humidity, flow circulation in blood vessels, pH, intensity of at least one predetermined wavelength of electromagnetic wave, sonic signal, concentration of at least one chemical compound, and their combinations thereof.
- the chemical compound is selected from the group consisting of glucose, sodium chloride, dimethyl sulfoxide, azone, isopropyl myristate, propylene glycol, Carbomer resins, gelling agents and their combinations thereof.
- the physical therapy is selected from the group consisting of mechanical stimulus, thermal stimulus, electrical stimulus, ultrasonic stimulus, magnetic stimulus, and irradiation of at least one predetermined wavelength.
- the medical device of this invention may further include attachment means for attaching the medical device to the patient.
- FIG. 1 shows the construction of a medical device of this invention
- FIG. 2 shows the logical structure of the controller in association with the actuator, sensor, and the communication module of the medical device of this invention
- FIG. 3 shows the flowchart of the operation of the sensors and the actuators of the device of this invention
- FIG. 4 shows exemplary preload therapy algorithms based on temperature difference between affected area and normal area of body
- FIG. 5 shows exemplary therapy algorithms based on patients individual healing condition with conditions reflected by temperature difference between affected and normal areas of the body.
- FIG. 1 shows a medical device ( 10 ) of this invention, which is in contact with the skin 50 of a patient.
- the device has at least one sensor ( 12 ) for measuring at least one parameter from the patient.
- Some parameters for example temperature, relative humidity, pH, and concentration of medication/drug/salts/fatty acid on the skin, can be measured from the skin of the patient.
- Conventional sensors can be used for obtaining these parameters.
- the following sensors can be used for this invention:
- a temperature sensor is used to measure the temperature on the skin surface. Temperature can be one of the parameters to determine the appropriate time to deliver the medicine to the treated area based on the elevation in local skin temperature beyond a certain threshold.
- a thermal couple can be used associated with another temperature sensor for cold junction reference to the ambient environment.
- temperature sensor Another type of temperature sensor is the transistor type sensor wherein it makes use of the fact that resistivity of the transistor changes with temperature. By monitoring the resistivity, the temperature can be deduced.
- the contact pressure applied by a cuff to the treated area will increase when there is inflammation on the treated area.
- a force sensor is applied to measure this pressure difference between inflamed and normal situations.
- This force sensor can be made of a semiconductor material, for example silicon, which will change its resistance when a force is applied.
- a constant voltage is applied to measure the variation in electrical current, which reflects the force change on the contact area.
- a humidity sensor is used to measure the local moisture above the skin surface when the medicine is applied. This information can be used as a parameter to optimize the drug delivery time, dose, and rate.
- a relative humidity sensor is made of a capacitor with polymer as a dielectric material. This polymer will change its dielectric constant when absorbing moisture, hence, variation in the measured capacitance of the capacitor reflects the humidity change. This capacitance difference will be translated to an electrical voltage by a driving circuit as a measurement of humidity change.
- a suitable sensor to determine the penetration rate of the chemical through the skin.
- concentration of chemicals including arthritis drug and/or insulin
- a suitable sensor to determine the penetration rate of the chemical through the skin.
- sensors that can create minimal discomfort to the patient when measuring these parameters. For example, many existing devices for measuring blood glucose level of patients suffering from diabetes can create less discomfort in most cases. The sensor would be specific for a given chemical.
- Gelling agents and Carbomer resins could also be detected by suitable sensors.
- Gelling agents are additives (usually in powder form) used to thicken and stabilize various liquid preparations, for example cosmetic cream. These gelling agents are usually hygroscopic in nature. When added to various liquid preparations, these polymers can swell to many times their original volume as they can absorb and retain water. Such swollen particles remain discrete in various mucilaginous or colloidal dispersions.
- the gelling agents provide the liquid with texture through formation of a gel.
- a gel is a colloidal system in which a porous network of interconnected particles spans the volume of a liquid medium. In general, gels are apparently solid, jelly-like materials.
- gels are mostly liquid in composition and thus exhibit densities similar to liquids, however have the structural coherence of a solid.
- An example of a common gel is edible gelatin.
- Typical gelling agents include natural gums, starches, pectins, agar-agar and gelatin. Often they are based on polysaccharides or proteins. Further examples of gelling agents include:
- Alginic acid (E400), sodium alginate (E401), potassium alginate (E402), ammonium alginate (E403), calcium alginate (E404)—polysaccharides from brown algae
- Agar (E406, a polysaccharide obtained from red seaweeds)
- Carrageenan (E407, a polysaccharide obtained from red seaweeds)
- Locust bean gum (E410, a natural gum from the seeds of the Carob tree)
- Pectin (E440, a polysaccharide obtained from apple or citrus-fruit)
- Carbomer 940 is a specific type of resins of the Carbomer series that is commonly used in cosmetic industry and acted as an emulsifying agent. These resins have low toxicity.
- These Carbomer resins (-910, -934, -934P, -940, -941, and -962) are synthetic, high molecular weight, nonlinear polymers of acrylic acid cross-linked with a polyalkenyl polyether. They are chemically similar to each other, differing only in ascending molecular weights (which range from Carbomer-910 to Carbomer-962). They contain between 98.7% and 99.9% acrylic acid. When dried at 80. degree. C. for one hour, they contain not less than 56.0% and not more than 68.0% carboxylic acid (—COOH) groups.
- the general structural formula is:
- sensors 12
- Some pressure, temperature and humidity sensors are made from micro-electrical mechanical systems MEMS and typically these are very small on the order of a few millimeter square and several millimeter thick. They can be conveniently incorporated into the system without taking much room and causing discomfort to users.
- Suitable sensors may include NTC Thermistor EC95 (thermocouple) from GETM, AD590 series from Analog DevicesTM, and FOT-HERO from Fiso Technologies for sensing temperatures; PX305/315 series from OmegaTM and NPC-100 from GETM for sensing pressure; Capactive SMD humidity sensor HC103/105 and HMX2200 from HygometrixTM for sensing humidity.
- NTC Thermistor EC95 thermocouple
- AD590 series from Analog DevicesTM
- FOT-HERO from Fiso Technologies for sensing temperatures
- PX305/315 series from OmegaTM and NPC-100 from GETM for sensing pressure
- Capactive SMD humidity sensor HC103/105 and HMX2200 from HygometrixTM for sensing humidity.
- the medical device ( 10 ) further includes an analyzer or controller ( 14 ) for analyzing the information obtained from the sensor ( 12 ), and determining what actions from the medical device are required to be performed on the patient.
- the controller ( 14 ) may be in the form of analog/digital converter, signal processor, microcontroller or CPU with suitable analog/digital converter and signal processor.
- the logical structure of the controller ( 14 ) is shown in FIG. 2 . After the parameters are measured and collected by the sensor ( 12 ), the parameters will then be analyzed by the controller ( 14 ). The controller ( 14 ) will then determine appropriate actions to be performed on the patient by the medical device ( 10 ) according to the analysis. Temperature, pressure, and humidity are measured by the respective sensors.
- FIG. 3 shows a flowchart of the operation of the sensors and the actuators of the device of this invention.
- the threshold levels would be determined by a person skilled in the art according to the different operation environment or the needs of the patient.
- the controller ( 14 ) can be an embedded system programmed with different types of therapies depending on the disease and the medical history of a given patient.
- the medical device ( 10 ) can perform specific therapy by sensing the patient's status, stimulates the patient by actuators ( 20 ), and logs the progress/status using internal memory. It can also be equipped with communication units, and user interface to facilitate the therapy purpose. Details of the controller ( 14 ) are explained as follows:
- the User Interface Module is responsible for presenting the users the real-time or historical system status such as sensor values, therapeutic programs, etc . . . , by means of LED, LCD, and buzzers, etc . . . . It is also responsible for accepting user inputs such as emergency stops, therapy activations, etc . . . by means of button presses, rotary switch, etc . . . . It is controlled and monitored by the Central Processing Unit to give the user a facility to interface with the Smart Device.
- CPU Central Processing Unit
- DSP Digital Signal Processor
- the CPU is responsible for the coordination of the User Interface Module, the Therapeutic Memory Module, the Actuator Controller, the Sensor Monitor, and Communication Module to perform a therapy sessions.
- the DSP is to perform the mathematical calculations and decision-making algorithms to realize an adaptable therapy session.
- the Therapeutic Memory Modules is responsible for the storage of the information for the Controllers relating primary to therapeutic information.
- the therapeutic information may have mainly 2 types.
- the 1st type is the preset therapy programs that are preloaded by users via the Communications Module.
- the 2nd type can be the therapy that is automatically adaptable to the ongoing therapy progress of the patients.
- the adaptation methods and outcomes are based on the mathematical calculations and decision-making algorithms of the CPU and DSPs.
- the therapy progress is monitored by calculating the variation gradient of the vital signs taken from the sensors, including those for detecting temperature, pressure, humidity, and pH.
- a proper therapy program will be selected from the pre-loaded therapy programs based on the calculated variation gradient of vital signs.
- the selection criteria can be of 2 folds.
- the first one is based on the clinical study from a group of patients to decide the proper drug dosage and electrical stimulus therapy for patients on different stages of improvement by applying the therapy. These criteria can be updated from the most recent clinical study to provide a better treatment for individual patients.
- the second one is based on the patients individual healing condition.
- the Therapeutic Memory Module shall correlated the healing condition, based on the sensors, and the therapeutic effect, based on drug dosage and electrical stimulus intensity; and formulates a personal treatment that adapts to a patients vital signs response to the treatment.
- FIG. 4 shows an exemplary preload therapy where all patients of ages 50-80 when under arthritis attack with measured temperature difference between arthritis affected area and normal area more than 3 degree Celsius, then medication Drug B of 15 mg is applied over the affected area.
- medication and dosage are applied based on individual's healing condition which is indicated by the temperature difference between affected area and normal area as shown in FIG. 5 .
- This procedure can be applied to any patient once the rules above are followed.
- the Communication Module is purely optional, and is responsible for gathering and delivering the information of the Controller from/to the external machine, such as PC, RFID-reader/writer, etc . . . , via wired and wireless means. It can be used for downloading therapy program, uploading therapy progress, and conveying Smart Device identity and capability, etc.
- the Actuator Controller is to control the actuator such as drug release, heater, and electrical stimulator in a timely and organized manner.
- the actuator of the drug can be a syringe pump, a rotary pump, a micro diaphragm pump, or a cartridge with back pressure and a valve to control its fluid releasing time.
- the selection of the pump could be based on the viscosity of the drug fluid and the required fluid flow rate.
- the syringe pump can be driven by a stepper motor with gear set to convert the rotary motion to the linear for pushing the plunger of the syringe forward or pulling it backward. This can pump or refill the drug to the syringe.
- a rotary pump can also be driven by a stepper motor with rotation of the gears to provide the required pumping force to the drug fluid.
- a micro diaphragm pump can be based on the vibration of a unimorph piezoelectrical metal disk to provide the actuation force, which pushes/pulls the fluid out of/into the pump chamber.
- the electronic pump drivers of the various pumps would be controlled by the microcontroller from the CPU.
- the actuation of the electrical stimulator can be initiated by a pulsed electrical voltage in, for example, the 70 to 90 volts high voltage range with connection to the skin treating location by a pair of conductive electrodes, for example graphite rubber pad or stainless steel fiber fabric.
- the high pulsed voltage can be boosted from a battery voltage by a boost converter circuit.
- the input digital signal of the driver circuit can also be provided from the microcontroller from the CPU, which performs as a central unit to control the drug release, the electrical stimulator, and the heater with digital signal feeding to the required actuator driver.
- the heater can be provided by joule heating from a conductive metal wire with designed heating power and area coverage with proper thermal and electrical isolation.
- the Sensor Monitor is to collect the sensing value of sensors such as temperature, pressure and humidity in a timely and organized manner.
- the medical device ( 10 ) has at least one actuator ( 20 ), which can exist in various different forms.
- Suitable actuators ( 20 ) include drug delivering devices in the form of injection device ( 22 ) or permeable membrane and valve ( 26 ), heater ( 24 ), electrodes ( 28 ), magnetic field generator (not shown in the figure), optical actuator (including Infra-red, ultraviolet), and sonic actuator including ultrasound.
- Providing actuators including heater ( 24 ), electrodes ( 28 ), magnetic field generator, optical actuator or sonic actuator (including ultrasound) may allow physical therapies to be performed in conjunction with drug delivery, which may enhance the overall therapeutic effects. Details of particularly preferred actuators are described as follows.
- a syringe pump can be used to pump the medicine fluid to the required treated area. It can be made of two parts.
- the first part is a syringe, which is similar to the regular syringe having a medicine container and a movable piston.
- a linear motor which is the second part, is provided.
- a piezoelectric linear motor is preferred for its miniature size and minimal number of parts, which can be made of a screw shaft and a nut attached with piezoelectric pads.
- a control circuitry with microcontroller on printed circuit board (PCB) can be used to drive the linear motor.
- a micro pump is another option for pumping liquid medicine to the treated area. Unlike a syringe pump, it separates the medicine cartridge from the pumping mechanism, which might ease the process of refilling the medicine by simply changing a new cartridge.
- a micro pump can be made of a piezoelectric actuated membrane with two valves, one on inlet and another one on outlet. As the membrane bending upward to increase the volume of the pump chamber, the inlet valve is opened and the outlet valve is closed to fill the pump chamber with a controlled volume. As the membrane bending downward to decrease the volume of the pump chamber, the inlet valve is closed and the outlet valve is opened to pump the liquid out of the chamber. These two processes cycle the liquid through the pump chamber to continuous pumping the liquid from the inlet to the outlet.
- the electro-stimulus device senses skin electrical resistance/current and applies a voltage to stimulate the nerve endings.
- An electric field/voltage will be applied in appropriate place in the sock to stimulate the local nerve endings and treat the inflamed area of the body.
- a heater pad is made of a metal wire actuated by joule heating, which can generate heat by passing an electrical current through the metal wire.
- This metal can be arranged in a planar serpentine shape to cover the required heating area, and a cloth to distribute the heat uniformly to the treated area.
- the magnetic field can be provided by a permanent magnet with a constant magnetic field or a magnetic coil to control the magnetic field by varying its electrical current.
- the ultrasonic transducer can be formed by piezoelectric composite materials. By applying an ac voltage to actuate the piezoelectric composite materials, an ultrasonic wave can be generated.
- the medical device ( 10 ) of this invention may include a removable drug cartridge ( 30 ) operably connected to the injection device ( 22 ) or permeable membrane and valve ( 26 ).
- the removable drug cartridge ( 30 ) contains the drug to be delivered to the user.
- the medical device ( 10 ) can have more than one removable drug cartridge ( 30 ). Although may be unified with the medical device ( 10 ) of this invention, the drug cartridge ( 30 ) is preferred to be removable for the ease of replenishment of drugs.
- the medical device ( 10 ) of this invention can allow suitable therapies in the form of drug delivery and/or physical therapies to be delivered to a patient at fixed time interval or according to the condition(s) of the patient as sensed by the sensors ( 12 ). This may provide improved effect over existing methods as therapies can be delivered to the patient at appropriate times.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physiology (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Current methods of delivering drug usually require a certain degree of human intervention. For example, a doctor, a paramedic or a patient is required to inject insulin manually when the blood sugar level becomes low. This invention provides a medical device for use with a patient for performing at least one of the functions of delivering drug and performing physical therapy to the patient. The device of this invention includes a sensor for measuring at least one parameter from the patient, an analyzer for analyzing the parameter to determine appropriate function to be carried out on the patient by said medical device, and at least one actuator to perform at least one of the functions of delivering drug and performing physical therapy.
Description
- This application is a divisional of U.S. application Ser. No. 11/790,426 filed on Apr. 25, 2007, the entire contents of which is incorporated herein by reference.
- This invention relates to medical device for use with a patient for delivering drug and/or performing physical therapy.
- Current methods of delivering drug usually require a certain degree of human intervention. For example, a doctor, a paramedic or a patient is required to inject insulin manually when the blood sugar level becomes low. In such a case, the patient's blood glucose level has to be monitored by certain devices. For arthritis attack over joints (finger joints, arm joints, knee joints or any other joints in the body), drugs may have to be applied transdermally to the affected area that could be inflamed and swollen. In such cases, the patient's joints need to be monitored by some means such as the skin temperature, symptoms of possible swell as a result of inflammation. Further, it has been found that the delivery of some drugs would be enhanced if physical therapy is applied simultaneously to patients over skin on the affected joint area. It would be advantageous if the patient can be treated by suitable drug administration and/or physical therapy at the right time. However, to the best of the inventors' knowledge, there is no existing device catering this need.
- Therefore, it is an object of this invention to provide medical devices that can delivery drug and/or provide physical therapy to a patient at appropriate time. It is also an object of this invention to resolve at least one or more of the problems as set forth in the prior art. As a minimum, it is an object of this invention to provide the public with a useful choice.
- Accordingly, this invention provides a medical device for use with a patient for performing at least one of the functions of delivering drug and performing physical therapy to the patient including:
- at least one sensor for measuring at least one parameter from the patient;
- an analyzer for analyzing the parameter to determine appropriate function to be carried out on the patient by said medical device; and
- at least one actuator to perform at least one of the functions of delivering drug and performing physical therapy.
- Preferably, the medical device of this invention may further include a drug storage unit for storing at least one drug, said drug storage unit being operatively connected to the actuator for delivering said drug to the patient.
- Preferably, the parameter is selected from the group consisting of electrical current or resistance, temperature, pressure, tension, humidity, flow circulation in blood vessels, pH, intensity of at least one predetermined wavelength of electromagnetic wave, sonic signal, concentration of at least one chemical compound, and their combinations thereof. More preferably, the chemical compound is selected from the group consisting of glucose, sodium chloride, dimethyl sulfoxide, azone, isopropyl myristate, propylene glycol, Carbomer resins, gelling agents and their combinations thereof.
- Advantageously, the physical therapy is selected from the group consisting of mechanical stimulus, thermal stimulus, electrical stimulus, ultrasonic stimulus, magnetic stimulus, and irradiation of at least one predetermined wavelength.
- Additionally, the medical device of this invention may further include attachment means for attaching the medical device to the patient.
- Preferred embodiments of the present invention will now be explained by way of example and with reference to the accompanying drawings in which:
-
FIG. 1 shows the construction of a medical device of this invention; -
FIG. 2 shows the logical structure of the controller in association with the actuator, sensor, and the communication module of the medical device of this invention; -
FIG. 3 shows the flowchart of the operation of the sensors and the actuators of the device of this invention; -
FIG. 4 shows exemplary preload therapy algorithms based on temperature difference between affected area and normal area of body; and -
FIG. 5 shows exemplary therapy algorithms based on patients individual healing condition with conditions reflected by temperature difference between affected and normal areas of the body. - This invention is now described by way of example with reference to the figures in the following paragraphs. List 1 is a part list so that the reference numerals in the figures may be easily referred to.
- Objects, features, and aspects of the present invention are disclosed in or are apparent from the following description. It is to be understood by one of ordinary skilled in the art that the present discussion is a description of exemplary embodiments only, and is not intended as limiting the broader aspects of the present invention, which broader aspects are embodied in the exemplary constructions.
-
FIG. 1 shows a medical device (10) of this invention, which is in contact with theskin 50 of a patient. The device has at least one sensor (12) for measuring at least one parameter from the patient. Some parameters, for example temperature, relative humidity, pH, and concentration of medication/drug/salts/fatty acid on the skin, can be measured from the skin of the patient. Conventional sensors can be used for obtaining these parameters. For example, the following sensors can be used for this invention: - A temperature sensor is used to measure the temperature on the skin surface. Temperature can be one of the parameters to determine the appropriate time to deliver the medicine to the treated area based on the elevation in local skin temperature beyond a certain threshold. A thermal couple can be used associated with another temperature sensor for cold junction reference to the ambient environment.
- Another type of temperature sensor is the transistor type sensor wherein it makes use of the fact that resistivity of the transistor changes with temperature. By monitoring the resistivity, the temperature can be deduced.
- The contact pressure applied by a cuff to the treated area will increase when there is inflammation on the treated area. A force sensor is applied to measure this pressure difference between inflamed and normal situations. This force sensor can be made of a semiconductor material, for example silicon, which will change its resistance when a force is applied. A constant voltage is applied to measure the variation in electrical current, which reflects the force change on the contact area.
- A humidity sensor is used to measure the local moisture above the skin surface when the medicine is applied. This information can be used as a parameter to optimize the drug delivery time, dose, and rate. A relative humidity sensor is made of a capacitor with polymer as a dielectric material. This polymer will change its dielectric constant when absorbing moisture, hence, variation in the measured capacitance of the capacitor reflects the humidity change. This capacitance difference will be translated to an electrical voltage by a driving circuit as a measurement of humidity change.
- The constructions of these sensors are known in the art, and therefore, would not be further discussed here.
- Other parameters, for example, concentration of chemicals including arthritis drug and/or insulin, on skin surface could be measured by a suitable sensor to determine the penetration rate of the chemical through the skin. There are existing sensors that can create minimal discomfort to the patient when measuring these parameters. For example, many existing devices for measuring blood glucose level of patients suffering from diabetes can create less discomfort in most cases. The sensor would be specific for a given chemical.
- Gelling agents and Carbomer resins could also be detected by suitable sensors. Gelling agents are additives (usually in powder form) used to thicken and stabilize various liquid preparations, for example cosmetic cream. These gelling agents are usually hygroscopic in nature. When added to various liquid preparations, these polymers can swell to many times their original volume as they can absorb and retain water. Such swollen particles remain discrete in various mucilaginous or colloidal dispersions. The gelling agents provide the liquid with texture through formation of a gel. On the other hand, a gel is a colloidal system in which a porous network of interconnected particles spans the volume of a liquid medium. In general, gels are apparently solid, jelly-like materials. Both by weight and volume, gels are mostly liquid in composition and thus exhibit densities similar to liquids, however have the structural coherence of a solid. An example of a common gel is edible gelatin. Typical gelling agents include natural gums, starches, pectins, agar-agar and gelatin. Often they are based on polysaccharides or proteins. Further examples of gelling agents include:
- Alginic acid (E400), sodium alginate (E401), potassium alginate (E402), ammonium alginate (E403), calcium alginate (E404)—polysaccharides from brown algae
- Agar (E406, a polysaccharide obtained from red seaweeds)
- Carrageenan (E407, a polysaccharide obtained from red seaweeds)
- Locust bean gum (E410, a natural gum from the seeds of the Carob tree)
- Pectin (E440, a polysaccharide obtained from apple or citrus-fruit)
- Gelatine (E441, made by partial hydrolysis of animal collagen)
- Carbomer 940 is a specific type of resins of the Carbomer series that is commonly used in cosmetic industry and acted as an emulsifying agent. These resins have low toxicity. These Carbomer resins (-910, -934, -934P, -940, -941, and -962) are synthetic, high molecular weight, nonlinear polymers of acrylic acid cross-linked with a polyalkenyl polyether. They are chemically similar to each other, differing only in ascending molecular weights (which range from Carbomer-910 to Carbomer-962). They contain between 98.7% and 99.9% acrylic acid. When dried at 80. degree. C. for one hour, they contain not less than 56.0% and not more than 68.0% carboxylic acid (—COOH) groups. The general structural formula is:
- Further details of Carbomer resins can be found in the article “Final Report on the Safety Assessment of Carbomers-934, -910, -934P, -940, -941, and -962” in “Polymers for Personal Care”, which is incorporated herein as a reference.
- Although the size of the sensors (12) should not affect the working of this invention, it would be apparent to a person skilled in the art that compact sensors are generally preferred. Some pressure, temperature and humidity sensors are made from micro-electrical mechanical systems MEMS and typically these are very small on the order of a few millimeter square and several millimeter thick. They can be conveniently incorporated into the system without taking much room and causing discomfort to users. Suitable sensors may include NTC Thermistor EC95 (thermocouple) from GE™, AD590 series from Analog Devices™, and FOT-HERO from Fiso Technologies for sensing temperatures; PX305/315 series from Omega™ and NPC-100 from GE™ for sensing pressure; Capactive SMD humidity sensor HC103/105 and HMX2200 from Hygometrix™ for sensing humidity.
- The medical device (10) further includes an analyzer or controller (14) for analyzing the information obtained from the sensor (12), and determining what actions from the medical device are required to be performed on the patient. The controller (14) may be in the form of analog/digital converter, signal processor, microcontroller or CPU with suitable analog/digital converter and signal processor. The logical structure of the controller (14) is shown in
FIG. 2 . After the parameters are measured and collected by the sensor (12), the parameters will then be analyzed by the controller (14). The controller (14) will then determine appropriate actions to be performed on the patient by the medical device (10) according to the analysis. Temperature, pressure, and humidity are measured by the respective sensors. When each of these measurements exceeds the predetermined threshold or tolerance levels, drug and or electrical stimulus could be applied to the affected area to sooth pain and reduce temperature of swollen area from inflammation due to arthritis attack.FIG. 3 shows a flowchart of the operation of the sensors and the actuators of the device of this invention. The threshold levels would be determined by a person skilled in the art according to the different operation environment or the needs of the patient. - The controller (14) can be an embedded system programmed with different types of therapies depending on the disease and the medical history of a given patient. The medical device (10) can perform specific therapy by sensing the patient's status, stimulates the patient by actuators (20), and logs the progress/status using internal memory. It can also be equipped with communication units, and user interface to facilitate the therapy purpose. Details of the controller (14) are explained as follows:
- The User Interface Module is responsible for presenting the users the real-time or historical system status such as sensor values, therapeutic programs, etc . . . , by means of LED, LCD, and buzzers, etc . . . . It is also responsible for accepting user inputs such as emergency stops, therapy activations, etc . . . by means of button presses, rotary switch, etc . . . . It is controlled and monitored by the Central Processing Unit to give the user a facility to interface with the Smart Device.
- The CPU is responsible for the coordination of the User Interface Module, the Therapeutic Memory Module, the Actuator Controller, the Sensor Monitor, and Communication Module to perform a therapy sessions. The DSP is to perform the mathematical calculations and decision-making algorithms to realize an adaptable therapy session.
- The Therapeutic Memory Modules is responsible for the storage of the information for the Controllers relating primary to therapeutic information. The therapeutic information may have mainly 2 types. The 1st type is the preset therapy programs that are preloaded by users via the Communications Module. The 2nd type can be the therapy that is automatically adaptable to the ongoing therapy progress of the patients. The adaptation methods and outcomes are based on the mathematical calculations and decision-making algorithms of the CPU and DSPs. The therapy progress is monitored by calculating the variation gradient of the vital signs taken from the sensors, including those for detecting temperature, pressure, humidity, and pH. A proper therapy program will be selected from the pre-loaded therapy programs based on the calculated variation gradient of vital signs. The selection criteria can be of 2 folds. The first one is based on the clinical study from a group of patients to decide the proper drug dosage and electrical stimulus therapy for patients on different stages of improvement by applying the therapy. These criteria can be updated from the most recent clinical study to provide a better treatment for individual patients. The second one is based on the patients individual healing condition. The Therapeutic Memory Module shall correlated the healing condition, based on the sensors, and the therapeutic effect, based on drug dosage and electrical stimulus intensity; and formulates a personal treatment that adapts to a patients vital signs response to the treatment.
-
FIG. 4 shows an exemplary preload therapy where all patients of ages 50-80 when under arthritis attack with measured temperature difference between arthritis affected area and normal area more than 3 degree Celsius, then medication Drug B of 15 mg is applied over the affected area. - On the other hand, medication and dosage are applied based on individual's healing condition which is indicated by the temperature difference between affected area and normal area as shown in
FIG. 5 . This procedure can be applied to any patient once the rules above are followed. - The Communication Module is purely optional, and is responsible for gathering and delivering the information of the Controller from/to the external machine, such as PC, RFID-reader/writer, etc . . . , via wired and wireless means. It can be used for downloading therapy program, uploading therapy progress, and conveying Smart Device identity and capability, etc.
- The Actuator Controller is to control the actuator such as drug release, heater, and electrical stimulator in a timely and organized manner. The actuator of the drug can be a syringe pump, a rotary pump, a micro diaphragm pump, or a cartridge with back pressure and a valve to control its fluid releasing time. The selection of the pump could be based on the viscosity of the drug fluid and the required fluid flow rate. The syringe pump can be driven by a stepper motor with gear set to convert the rotary motion to the linear for pushing the plunger of the syringe forward or pulling it backward. This can pump or refill the drug to the syringe. A rotary pump can also be driven by a stepper motor with rotation of the gears to provide the required pumping force to the drug fluid. A micro diaphragm pump can be based on the vibration of a unimorph piezoelectrical metal disk to provide the actuation force, which pushes/pulls the fluid out of/into the pump chamber. The electronic pump drivers of the various pumps would be controlled by the microcontroller from the CPU.
- The actuation of the electrical stimulator can be initiated by a pulsed electrical voltage in, for example, the 70 to 90 volts high voltage range with connection to the skin treating location by a pair of conductive electrodes, for example graphite rubber pad or stainless steel fiber fabric. The high pulsed voltage can be boosted from a battery voltage by a boost converter circuit. The input digital signal of the driver circuit can also be provided from the microcontroller from the CPU, which performs as a central unit to control the drug release, the electrical stimulator, and the heater with digital signal feeding to the required actuator driver. The heater can be provided by joule heating from a conductive metal wire with designed heating power and area coverage with proper thermal and electrical isolation.
- The Sensor Monitor is to collect the sensing value of sensors such as temperature, pressure and humidity in a timely and organized manner.
- For performing the required actions on the patient, the medical device (10) has at least one actuator (20), which can exist in various different forms. Suitable actuators (20) include drug delivering devices in the form of injection device (22) or permeable membrane and valve (26), heater (24), electrodes (28), magnetic field generator (not shown in the figure), optical actuator (including Infra-red, ultraviolet), and sonic actuator including ultrasound. Providing actuators including heater (24), electrodes (28), magnetic field generator, optical actuator or sonic actuator (including ultrasound) may allow physical therapies to be performed in conjunction with drug delivery, which may enhance the overall therapeutic effects. Details of particularly preferred actuators are described as follows.
- A syringe pump can be used to pump the medicine fluid to the required treated area. It can be made of two parts. The first part is a syringe, which is similar to the regular syringe having a medicine container and a movable piston. As the piston moves forward, the enclosed volume of the syringe container is decreased and a controlled volume of the liquid medicine is ejected. To move the piston automatically, a linear motor, which is the second part, is provided. A piezoelectric linear motor is preferred for its miniature size and minimal number of parts, which can be made of a screw shaft and a nut attached with piezoelectric pads. When two opposite sides of the piezoelectric pads are actuated by two sinusoidal electrical voltage waves with half-wave phase shift, a hula-hoop motion on the screw nut is generated, rotating the screw shaft and moving it forward or backward depending on the electrical control. A control circuitry with microcontroller on printed circuit board (PCB) can be used to drive the linear motor.
- A micro pump is another option for pumping liquid medicine to the treated area. Unlike a syringe pump, it separates the medicine cartridge from the pumping mechanism, which might ease the process of refilling the medicine by simply changing a new cartridge. A micro pump can be made of a piezoelectric actuated membrane with two valves, one on inlet and another one on outlet. As the membrane bending upward to increase the volume of the pump chamber, the inlet valve is opened and the outlet valve is closed to fill the pump chamber with a controlled volume. As the membrane bending downward to decrease the volume of the pump chamber, the inlet valve is closed and the outlet valve is opened to pump the liquid out of the chamber. These two processes cycle the liquid through the pump chamber to continuous pumping the liquid from the inlet to the outlet.
- The electro-stimulus device senses skin electrical resistance/current and applies a voltage to stimulate the nerve endings. An electric field/voltage will be applied in appropriate place in the sock to stimulate the local nerve endings and treat the inflamed area of the body.
- A heater pad is made of a metal wire actuated by joule heating, which can generate heat by passing an electrical current through the metal wire. This metal can be arranged in a planar serpentine shape to cover the required heating area, and a cloth to distribute the heat uniformly to the treated area.
- It is known that muscles can be relaxed in the presence of a weak magnetic field over the body. This relaxed portion could also have an added benefit of improving diffusion of drugs over skin with increased pore size and thus skin permeability. The magnetic field can be provided by a permanent magnet with a constant magnetic field or a magnetic coil to control the magnetic field by varying its electrical current.
- A small device for generating ultrasound at mega hertz range, from 1 to 3 MHz, could be used to sooth the patient's body, including the reduction of pain on the joints. When ultrasonic waves are transmitted to the tissue, a thermal effect would be generated to reduce inflammation, and the mobility and flexibility of the joints could also be increased. The ultrasonic transducer can be formed by piezoelectric composite materials. By applying an ac voltage to actuate the piezoelectric composite materials, an ultrasonic wave can be generated.
- There are garments or fabrics that absorb ultraviolet light from the sun and converted photons to infra-red emission that could be helpful in treating the body with thermal healing effect.
- The construction of the above actuators is generally known in the art, and therefore, will not be described further.
- The medical device (10) of this invention may include a removable drug cartridge (30) operably connected to the injection device (22) or permeable membrane and valve (26). The removable drug cartridge (30) contains the drug to be delivered to the user. The medical device (10) can have more than one removable drug cartridge (30). Although may be unified with the medical device (10) of this invention, the drug cartridge (30) is preferred to be removable for the ease of replenishment of drugs.
- The medical device (10) of this invention can allow suitable therapies in the form of drug delivery and/or physical therapies to be delivered to a patient at fixed time interval or according to the condition(s) of the patient as sensed by the sensors (12). This may provide improved effect over existing methods as therapies can be delivered to the patient at appropriate times.
- While the preferred embodiment of the present invention has been described in detail by the examples, it is apparent that modifications and adaptations of the present invention will occur to those skilled in the art. Furthermore, the embodiments of the present invention shall not be interpreted to be restricted by the examples or figures only. It is to be expressly understood, however, that such modifications and adaptations are within the scope of the present invention, as set forth in the following claims. For instance, features illustrated or described as part of one embodiment can be used on another embodiment to yield a still further embodiment. Thus, it is intended that the present invention cover such modifications and variations as come within the scope of the claims and their equivalents.
- TABLE-US-00001 List 1
Reference Numerals Description 10Medical device 12Sensor 14Controller 20Actuators 24Heater 26 Semi-permeable membrane and/orvalve 28Electrodes 30Removable drug storage 50 Skin of an user
Claims (22)
1. A medical device for use in delivering a drug to a patient, the device including:
at least one sensor for measuring at least one parameter of the patient;
an analyzer for analyzing the parameter of the patient;
at least one actuator for delivering the drug to the patient via a portion of the patient's skin in response to the analyzed parameter; and
at least one actuator for applying a physical therapy to the patient at the portion of the person's skin substantially simultaneously with delivery of the drug to the patient.
2. The medical device of claim 1 including a drug storage unit for storing at least one drug, said drug storage unit being operatively connected to the actuator for delivering said drug to the patient.
3. The medical device of claim 1 , wherein the parameter is selected from a group including electrical current or resistance, temperature, pressure, tension, humidity, flow circulation in blood vessels, pH, intensity of at least one predetermined wavelength of electromagnetic wave, sonic signal, concentration of at least one chemical compound, and their combinations thereof.
4. The medical device of claim 3 , wherein said chemical compound is selected from a group including glucose, sodium chloride, dimethyl sulfoxide, azone, isopropyl myristate, propylene glycol, Carbomer resins, gelling agents and their combinations thereof.
5. The medical device of claim 1 , wherein the physical therapy is selected from a group including mechanical stimulus, temperature stimulus, ultrasonic stimulus, magnetic stimulus, and irradiation of at least one predetermined wavelength.
6. The medical device of claim 1 including an attachment means for attaching the medical device to the patient.
7. A method of delivering a drug to a patient using a medical device, the method including the steps of:
measuring at least one parameter of the patient;
analyzing the parameter of the patient;
delivering the drug to the patient via a portion of the patient's skin in response to the analyzed parameter;
wherein a physical therapy is simultaneously applied to the portion of the person's skin during delivery of the drug to the patient.
8. The method of claim 7 wherein the medical device includes a drug storage unit for storing at least one drug, said drug storage unit being operatively connected to the actuator for delivering said drug to the patient.
9. The method of claim 7 , wherein the parameter is selected from a group including electrical current or resistance, temperature, pressure, tension, humidity, flow circulation in blood vessels, pH, intensity of at least one predetermined wavelength of electromagnetic wave, sonic signal, concentration of at least one chemical compound, and their combinations thereof.
10. The method of claim 9 , wherein said chemical compound is selected from a group including glucose, sodium chloride, dimethyl sulfoxide, azone, isopropyl myristate, propylene glycol, Carbomer resins, gelling agents and their combinations thereof.
11. The method of claim 7 , wherein the physical therapy is selected from a group including mechanical stimulus, temperature stimulus, ultrasonic stimulus, magnetic stimulus, and irradiation of at least one predetermined wavelength.
12. The method of claim 7 including the step of attaching the medical device to the patient.
13. A medical device for use in applying a physical therapy to a patient, the device including:
at least one sensor for measuring at least one parameter of the patient;
an analyzer for analyzing the parameter; and
at least one actuator to apply the physical therapy to the patient in response to the analyzed parameter.
14. The medical device of claim 13 , wherein the parameter is selected from a group including electrical current or resistance, temperature, pressure, tension, humidity, flow circulation in blood vessels, pH, intensity of at least one predetermined wavelength of electromagnetic wave, sonic signal, concentration of at least one chemical compound, and their combinations thereof.
15. The medical device of claim 14 , wherein said chemical compound is selected from a group including glucose, sodium chloride, dimethyl sulfoxide, azone, isopropyl myristate, propylene glycol, Carbomer resins, gelling agents and their combinations thereof.
16. The medical device of claim 13 , wherein the physical therapy is selected from a group including mechanical stimulus, temperature stimulus, electrical stimulus, ultrasonic stimulus, magnetic stimulus, and irradiation of at least one predetermined wavelength.
17. The medical device of claim 13 including an attachment means for attaching the medical device to the patient.
18. A method for applying a physical therapy to a patient using a medical device, said method including the steps of:
measuring at least one parameter of the patient;
analyzing the measured parameter; and
applying the physical therapy to the patient in response to the analyzed parameter.
19. The method of claim 18 , wherein the parameter is selected from a group including electrical current or resistance, temperature, pressure, tension, humidity, flow circulation in blood vessels, pH, intensity of at least one predetermined wavelength of electromagnetic wave, sonic signal, concentration of at least one chemical compound, and their combinations thereof.
20. The method of claim 19 , wherein said chemical compound is selected from a group including glucose, sodium chloride, dimethyl sulfoxide, azone, isopropyl myristate, propylene glycol, Carbomer resins, gelling agents and their combinations thereof.
21. The method of claim 18 , wherein the physical therapy is selected from a group including mechanical stimulus, temperature stimulus, electrical stimulus, ultrasonic stimulus, magnetic stimulus, and irradiation of at least one predetermined wavelength.
22. The method of claim 18 further including the step of attaching the medical device to the patient by an attachment means.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/164,293 US20110245580A1 (en) | 2007-04-25 | 2011-06-20 | Medical device for delivering drug and/or performing physical therapy |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/790,426 US7998110B2 (en) | 2007-04-25 | 2007-04-25 | Medical device for delivering drug and/or performing physical therapy |
| US13/164,293 US20110245580A1 (en) | 2007-04-25 | 2011-06-20 | Medical device for delivering drug and/or performing physical therapy |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/790,426 Division US7998110B2 (en) | 2007-04-25 | 2007-04-25 | Medical device for delivering drug and/or performing physical therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20110245580A1 true US20110245580A1 (en) | 2011-10-06 |
Family
ID=39887799
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/790,426 Active 2029-12-17 US7998110B2 (en) | 2007-04-25 | 2007-04-25 | Medical device for delivering drug and/or performing physical therapy |
| US13/164,293 Abandoned US20110245580A1 (en) | 2007-04-25 | 2011-06-20 | Medical device for delivering drug and/or performing physical therapy |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/790,426 Active 2029-12-17 US7998110B2 (en) | 2007-04-25 | 2007-04-25 | Medical device for delivering drug and/or performing physical therapy |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US7998110B2 (en) |
| EP (1) | EP2142244A4 (en) |
| TW (1) | TW200916136A (en) |
| WO (1) | WO2008131684A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110117151A1 (en) * | 2009-11-13 | 2011-05-19 | Searete Llc. A Limited Liability Corporation Of The State Of Delaware | Device,system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US20110118698A1 (en) * | 2009-11-13 | 2011-05-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US20110118560A1 (en) * | 2009-11-13 | 2011-05-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| WO2018142296A3 (en) * | 2017-02-01 | 2018-10-11 | Zion Azar | Systems methods devices apparatuses circuits and computer executable code for production and topical application of a therapeutic substance |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
| US8912908B2 (en) | 2005-04-28 | 2014-12-16 | Proteus Digital Health, Inc. | Communication system with remote activation |
| EP3827747A1 (en) | 2005-04-28 | 2021-06-02 | Otsuka Pharmaceutical Co., Ltd. | Pharma-informatics system |
| US8836513B2 (en) | 2006-04-28 | 2014-09-16 | Proteus Digital Health, Inc. | Communication system incorporated in an ingestible product |
| WO2008112578A1 (en) | 2007-03-09 | 2008-09-18 | Proteus Biomedical, Inc. | In-body device having a deployable antenna |
| US7922695B2 (en) | 2007-10-18 | 2011-04-12 | Roche Diagnostics Operations, Inc. | Drug delivery pump drive using linear piezoelectric motor |
| AU2009281876B2 (en) | 2008-08-13 | 2014-05-22 | Proteus Digital Health, Inc. | Ingestible circuitry |
| US8284572B2 (en) * | 2008-11-20 | 2012-10-09 | Leadtrend Technology Corp. | Current control method and apparatus |
| CA2748071C (en) * | 2009-01-16 | 2014-06-03 | The Procter & Gamble Company | Apparatus and methods for modifying keratinous surfaces |
| WO2010111403A2 (en) | 2009-03-25 | 2010-09-30 | Proteus Biomedical, Inc. | Probablistic pharmacokinetic and pharmacodynamic modeling |
| BR122013009559A2 (en) | 2009-04-28 | 2019-08-06 | Proteus Digital Health, Inc. | HIGHLY RELIABLE INGESIBLE EVENT MARKERS AND METHODS FOR USING THEM |
| CA2921304C (en) | 2009-07-30 | 2018-06-05 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
| RU2012143791A (en) | 2010-04-07 | 2014-05-20 | Проутьюс Диджитал Хэлс, Инк. | MINIATURE INGESTED DEVICE |
| JP2014504902A (en) | 2010-11-22 | 2014-02-27 | プロテウス デジタル ヘルス, インコーポレイテッド | Ingestible device with medicinal product |
| US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
| WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
| CN104245014B (en) * | 2012-01-31 | 2017-05-24 | 麦迪麦珀医疗项目有限公司 | Time-Dependent Drug Delivery Devices |
| US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
| US9381297B2 (en) | 2012-06-07 | 2016-07-05 | Tandem Diabetes Care, Inc. | Sealed infusion device with electrical connector port |
| US9271897B2 (en) | 2012-07-23 | 2016-03-01 | Proteus Digital Health, Inc. | Techniques for manufacturing ingestible event markers comprising an ingestible component |
| TWI659994B (en) | 2013-01-29 | 2019-05-21 | 美商普羅托斯數位健康公司 | Highly-swellable polymeric films and compositions comprising the same |
| US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
| US20150182163A1 (en) * | 2013-12-31 | 2015-07-02 | Aliphcom | Wearable device to detect inflamation |
| US10175376B2 (en) | 2013-03-15 | 2019-01-08 | Proteus Digital Health, Inc. | Metal detector apparatus, system, and method |
| US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
| US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
| CA2936247A1 (en) | 2014-01-22 | 2015-07-30 | Marcio Marc Abreu | Devices and methods for transdermal drug delivery |
| US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
| EP4104878A1 (en) | 2015-08-20 | 2022-12-21 | Tandem Diabetes Care, Inc. | Drive mechanism for infusion pump |
| CN107049741A (en) * | 2016-02-05 | 2017-08-18 | 微传智能科技(上海)有限公司 | Intelligent prostate physical therapeutic system and its modality control method |
| EP3448467B1 (en) * | 2016-04-28 | 2021-03-31 | Becton, Dickinson and Company | System for medication dose capture with flow patch and delivery informatics |
| WO2018018034A1 (en) | 2016-07-22 | 2018-01-25 | Proteus Digital Health, Inc. | Electromagnetic sensing and detection of ingestible event markers |
| EP3490635B1 (en) | 2016-08-01 | 2021-11-17 | West Pharma. Services Il, Ltd. | Partial door closure prevention spring |
| JP2019535377A (en) | 2016-10-26 | 2019-12-12 | プロテウス デジタル ヘルス, インコーポレイテッド | Method for producing capsules with ingestible event markers |
| JP6921997B2 (en) | 2017-05-30 | 2021-08-18 | ウェスト ファーマ サービシーズ イスラエル リミテッド | Modular drive train for wearable syringes |
| WO2019152908A1 (en) | 2018-02-05 | 2019-08-08 | Tandem Diabetes Care, Inc. | Methods and systems for detecting infusion pump conditions |
| CN108853720A (en) * | 2018-05-16 | 2018-11-23 | 邱骅轩 | A kind of adaptive transdermal iontophoretic method import system for beauty treatment fields |
| US11464908B2 (en) | 2019-02-18 | 2022-10-11 | Tandem Diabetes Care, Inc. | Methods and apparatus for monitoring infusion sites for ambulatory infusion pumps |
| JP2023507622A (en) * | 2019-12-18 | 2023-02-24 | デックスコム・インコーポレーテッド | therapeutic zone identifier |
| CN114949576B (en) * | 2022-07-27 | 2022-11-11 | 北京神州汉方医药科技有限公司 | Drug administration control device for skin drug administration |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5421816A (en) * | 1992-10-14 | 1995-06-06 | Endodermic Medical Technologies Company | Ultrasonic transdermal drug delivery system |
| US5551953A (en) * | 1994-10-31 | 1996-09-03 | Alza Corporation | Electrotransport system with remote telemetry link |
| US6652473B2 (en) * | 1999-01-15 | 2003-11-25 | Jonathan J. Kaufman | Ultrasonic and growth factor bone-therapy: apparatus and method |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5135479A (en) * | 1983-08-18 | 1992-08-04 | Drug Delivery Systems, Inc. | Programmable control and mounting system for transdermal drug applicator |
| CA2256481A1 (en) * | 1996-05-31 | 1997-12-04 | The National American Red Cross | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids |
| US6059736A (en) * | 1998-02-24 | 2000-05-09 | Tapper; Robert | Sensor controlled analysis and therapeutic delivery system |
| US6969382B2 (en) * | 1999-07-26 | 2005-11-29 | Zuli Holdings, Ltd. | Method and apparatus for treating bodily tissues with medicinal substance |
| US20050075598A1 (en) * | 2001-08-24 | 2005-04-07 | Redding Bruce K. | Method and apparatus for the measurement of real time drug delivery through the use of a wearable monitor and sensor attached to a transdermal drug delivery device |
| US6723077B2 (en) * | 2001-09-28 | 2004-04-20 | Hewlett-Packard Development Company, L.P. | Cutaneous administration system |
| KR100725973B1 (en) * | 2002-08-16 | 2007-06-11 | 마이크로칩스 인코포레이티드 | Controlled Release Device and Method Using Electrothermal Removal |
| JP2006524120A (en) * | 2003-04-21 | 2006-10-26 | ストラテージェント ライフ サイエンシズ | Apparatus and method for repetitively delivering drug by microjet |
| EP1662987B1 (en) * | 2003-09-11 | 2011-11-09 | Theranos, Inc. | Medical device for analyte monitoring and drug delivery |
| WO2005089646A1 (en) * | 2004-03-16 | 2005-09-29 | Medtronic, Inc. | Sensitivity analysis for selecting therapy parameter sets |
| WO2006015299A2 (en) * | 2004-07-30 | 2006-02-09 | Microchips, Inc. | Multi-reservoir device for transdermal drug delivery and sensing |
-
2007
- 2007-04-25 US US11/790,426 patent/US7998110B2/en active Active
-
2008
- 2008-04-24 TW TW097115020A patent/TW200916136A/en unknown
- 2008-04-25 EP EP08734166A patent/EP2142244A4/en not_active Withdrawn
- 2008-04-25 WO PCT/CN2008/070808 patent/WO2008131684A1/en not_active Ceased
-
2011
- 2011-06-20 US US13/164,293 patent/US20110245580A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5421816A (en) * | 1992-10-14 | 1995-06-06 | Endodermic Medical Technologies Company | Ultrasonic transdermal drug delivery system |
| US5551953A (en) * | 1994-10-31 | 1996-09-03 | Alza Corporation | Electrotransport system with remote telemetry link |
| US6652473B2 (en) * | 1999-01-15 | 2003-11-25 | Jonathan J. Kaufman | Ultrasonic and growth factor bone-therapy: apparatus and method |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110117151A1 (en) * | 2009-11-13 | 2011-05-19 | Searete Llc. A Limited Liability Corporation Of The State Of Delaware | Device,system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US20110118698A1 (en) * | 2009-11-13 | 2011-05-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US20110118652A1 (en) * | 2009-11-13 | 2011-05-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device,system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US20110118695A1 (en) * | 2009-11-13 | 2011-05-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US20110118697A1 (en) * | 2009-11-13 | 2011-05-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US20110118560A1 (en) * | 2009-11-13 | 2011-05-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US20110118696A1 (en) * | 2009-11-13 | 2011-05-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US20110118656A1 (en) * | 2009-11-13 | 2011-05-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US20110118653A1 (en) * | 2009-11-13 | 2011-05-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US8419707B2 (en) | 2009-11-13 | 2013-04-16 | The Invention Science Fund I, Llc | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US8439896B2 (en) | 2009-11-13 | 2013-05-14 | The Invention Science Fund I, Llc | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US8444622B2 (en) * | 2009-11-13 | 2013-05-21 | The Invention Science Fund I, Llc | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US8784368B2 (en) | 2009-11-13 | 2014-07-22 | The Invention Science Fund I, Llc | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US8888761B2 (en) | 2009-11-13 | 2014-11-18 | The Invention Science Fund I, Llc | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US8894630B2 (en) | 2009-11-13 | 2014-11-25 | The Invention Science Fund I, Llc | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US8926584B2 (en) | 2009-11-13 | 2015-01-06 | The Invention Science Fund I, Llc | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US9050303B2 (en) | 2009-11-13 | 2015-06-09 | The Invention Science Fund I, Llc | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| US9078863B2 (en) | 2009-11-13 | 2015-07-14 | The Invention Science Fund I, Llc | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
| WO2018142296A3 (en) * | 2017-02-01 | 2018-10-11 | Zion Azar | Systems methods devices apparatuses circuits and computer executable code for production and topical application of a therapeutic substance |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2142244A4 (en) | 2013-03-27 |
| US20080269570A1 (en) | 2008-10-30 |
| EP2142244A1 (en) | 2010-01-13 |
| WO2008131684A1 (en) | 2008-11-06 |
| US7998110B2 (en) | 2011-08-16 |
| TW200916136A (en) | 2009-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7998110B2 (en) | Medical device for delivering drug and/or performing physical therapy | |
| US12011584B2 (en) | Devices, methods, and systems for the treatment and/or monitoring of damaged tissue | |
| CN113226448A (en) | Method and apparatus for a wearable electronic digital treatment device | |
| CN101715354B (en) | Methods and devices for drug delivery | |
| JPH06208A (en) | Pumping equipment for medical treatment | |
| US20090209828A1 (en) | Method and device microcalorimetrically measuring a tissue local metabolism speed, intracellular tissue water content, blood biochemical component concentration and a cardio-vascular system tension | |
| EP2244678A2 (en) | Device and method for enhanced wound treatment | |
| Yum et al. | Smart triboelectric nanogenerators toward human‐oriented technologies: Health monitoring, wound healing, drug delivery | |
| CN117442163A (en) | Postoperative lymphedema early warning method and device based on intelligent wearable equipment | |
| CN113520787A (en) | Interactive wearable device for perioperative period of total knee replacement | |
| Liu et al. | Bioinspired Intelligent Electronic Skin for Medicine and Healthcare | |
| CN203001680U (en) | Real-time measuring and control type intelligent heat dosage hot compressing therapeutic instrument | |
| CN119055944A (en) | Microneedle patch and drug delivery control method | |
| Rosa et al. | A New Approach to Treating Symptoms of Diabetes Mellitus | |
| KR200186494Y1 (en) | An ultrasonic bathtub for foot using a chinese medicine | |
| CN119075163B (en) | Self-powered wearable integrated diagnosis and treatment patch for atopic dermatitis, preparation method, and application | |
| Durmuş et al. | Investigation of temperature effects of a low-level laser source within the muscle phantom | |
| Wang | Soft Electronics for Medical Treatment | |
| CN115397381B (en) | System and method for providing an oscillating motion to an individual | |
| US20240366469A1 (en) | Devices and systems for providing compression and/or vibratory forces to tissues | |
| KR20010018349A (en) | An ultrasonic bathtub for foot using a chinese medicine | |
| Narayanan et al. | Pharmacoelectronics and electropharmaceutics: the arts and science of electronic drug delivery | |
| Madhu et al. | Smart and Sustainable Approaches for Wound Care | |
| FI121215B (en) | A system for delivering a substance to a destination | |
| JPH04300562A (en) | Electrical drug introducing device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |